Intellia Therapeutics Inc (NTLA)

09:06 AM

Is Intellia Therapeutics Inc. (38I) stock a buy on weaknessPortfolio Return Report & AI Powered Trade Plan Recommendations - newser.com

09:06 AM

03:35 AM

Gene Editing Market Size to Surpass USD 42.13 Billion by 2034 - GlobeNewswire Inc.

03:35 AM

01:37 AM

Can technical indicators confirm Intellia Therapeutics Inc.’s reversal2025 Dividend Review & Stepwise Trade Execution Plans - newser.com

01:37 AM

Nov 03, 2025

How Intellia Therapeutics Inc. stock reacts to oil pricesQuarterly Trade Report & Verified Momentum Stock Alerts - newser.com

Nov 03, 2025

Nov 03, 2025

Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – NTLA - 2822news.com

Nov 03, 2025

Nov 03, 2025

What technical models suggest about Intellia Therapeutics Inc.’s comebackJuly 2025 Action & Community Consensus Stock Picks - newser.com

Nov 03, 2025

Nov 03, 2025

Intellia Gears Up to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research

Nov 03, 2025

Nov 03, 2025

Is Intellia Therapeutics Inc. still worth holding after the dipInflation Watch & Verified Short-Term Trading Plans - newser.com

Nov 03, 2025

Nov 03, 2025

Chart overlay techniques for tracking Intellia Therapeutics Inc.2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com

Nov 03, 2025

Nov 03, 2025

Pinnacle Associates Ltd. Sells 45,470 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat

Nov 03, 2025

Nov 03, 2025

How sentiment analysis helps forecast Intellia Therapeutics Inc.Market Growth Report & Growth Oriented Trade Recommendations - newser.com

Nov 03, 2025

Nov 03, 2025

AlphaQuest LLC Sells 29,619 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat

Nov 03, 2025

Nov 03, 2025

Real time scanner hits for Intellia Therapeutics Inc. explainedQuarterly Trade Summary & Weekly Chart Analysis and Trade Guides - newser.com

Nov 03, 2025

Nov 02, 2025

How cyclical is Intellia Therapeutics Inc. (38I) stock compared to rivalsJuly 2025 WrapUp & Weekly Watchlist of Top Performers - newser.com

Nov 02, 2025

Nov 02, 2025

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - sharewise.com

Nov 02, 2025

Nov 02, 2025

Should You Buy Viking Therapeutics Before Nov. 5? - AOL.com

Nov 02, 2025

Nov 02, 2025

Can a trend reversal in Intellia Therapeutics Inc. lead to recoveryJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - newser.com

Nov 02, 2025

Nov 02, 2025

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat

Nov 02, 2025

Nov 02, 2025

Is Intellia Therapeutics Inc. (38I) stock trading at attractive multiples2025 Dividend Review & Short-Term High Return Ideas - newser.com

Nov 02, 2025

Nov 02, 2025

Will Intellia Therapeutics Inc. (38I) stock benefit from sector leadershipWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com

Nov 02, 2025

Nov 01, 2025

Relative strength of Intellia Therapeutics Inc. in sector analysisTrade Signal Summary & AI Forecasted Entry/Exit Points - newser.com

Nov 01, 2025

Nov 01, 2025

Intellia Therapeutics (NTLA) Is Down 50.7% After FDA Halts MAGNITUDE Trials on Safety Concerns – Has The Bull Case Changed? - Sahm

Nov 01, 2025

Nov 01, 2025

Leerink Partnrs Has Positive Estimate for NTLA Q3 Earnings - MarketBeat

Nov 01, 2025

Nov 01, 2025

What to expect from Intellia Therapeutics Inc. in the next 30 days2025 Analyst Calls & Momentum Based Trading Signals - newser.com

Nov 01, 2025

Oct 31, 2025

Intellia Therapeutics Inc. (NTLA) Stock Price | Live Quotes & Charts | NSD - StocksToTrade

Oct 31, 2025

Oct 31, 2025

Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says - MarketScreener

Oct 31, 2025

Oct 31, 2025

SA analyst upgrades/downgrades: AMZN, NVDA, CMG, NTLA - Seeking Alpha

Oct 31, 2025

Oct 31, 2025

Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease - MedCity News

Oct 31, 2025

Oct 31, 2025

Intellia Therapeutics: Irreversible Edit Vs. Reversible SOCs Now A Hard Sell (Rating Downgrade) - Seeking Alpha

Oct 31, 2025

Oct 31, 2025

Gene-editing stocks rally on Bloomberg report that FDA plans to fast-track approval process - Sherwood News

Oct 31, 2025

Oct 31, 2025

FDA Clears Way for Faster Personalized Gene Editing Therapy - Bloomberg.com

Oct 31, 2025

Oct 31, 2025

NTLA FY2027 EPS Reduced by Brookline Capital Management - MarketBeat

Oct 31, 2025

Oct 31, 2025

What is Leerink Partnrs' Estimate for NTLA FY2027 Earnings? - MarketBeat

Oct 31, 2025

Oct 31, 2025

Is a relief rally coming for Intellia Therapeutics Inc. holders2025 Retail Activity & Free Real-Time Market Sentiment Alerts - newser.com

Oct 31, 2025

Oct 31, 2025

Analyzing drawdowns of Intellia Therapeutics Inc. with statistical tools2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com

Oct 31, 2025

Oct 31, 2025

Will Intellia Therapeutics Inc. stock benefit from AI adoptionJobs Report & Growth Oriented Trading Recommendations - newser.com

Oct 31, 2025

Oct 31, 2025

Is Intellia Therapeutics Inc. stock oversold or undervaluedMarket Volume Summary & Free Technical Pattern Based Buy Signals - newser.com

Oct 31, 2025

Oct 30, 2025

Intellia Therapeutics Faces FDA Clinical Hold on Trials - The Globe and Mail

Oct 30, 2025

Oct 30, 2025

Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade) - Seeking Alpha

Oct 30, 2025

Oct 30, 2025

NTLA Stock: Plummet Unlocks Market Debate? - StocksToTrade

Oct 30, 2025

Oct 30, 2025

Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 7.9% on Analyst Downgrade - MarketBeat

Oct 30, 2025

Oct 30, 2025

HC Wainwright & Co. Lowers NTLA Price Target to $18, Maintains B - GuruFocus

Oct 30, 2025

Oct 30, 2025

FDA places formal hold on two Intellia CRISPR trials - BioPharma Dive

Oct 30, 2025